Prakt. lékáren. 2009; 5(4): 189-193

Medicinal Cannabis and related medicinal preparations

Mgr. Jaroslav Peč, doc. RNDr. Jaroslav Dušek CSc
Katedra farmakognosie, FaF v Hradci Králové

Submited article deals with therapeutic potential of cannabis metabolites. The cannabinoids as well as other bioactive secondary

metabolites are introduced. Medicinal preparations based on the research of cannabinoids and human endocannabinoid system with

dosage in particular indications are presented. In the following the crude cannabis drug is characterized. The Czech Republic legal provision

concerning cannabis usage in pharmacotherapy is presented. The psychoactive abused potential of cannabis is briefly mentioned,

especially with the emphasis on possible risks and the development of dependence.

Keywords: Cannabis sativa, cannabis, secondary metabolites, cannabinoids, Cesamet, Marinol, Sativex, Cannabis flos.

Published: August 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Peč J, Dušek J. Medicinal Cannabis and related medicinal preparations. Praktické lékárenství. 2009;5(4):189-193.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Guy GW, Whittle BA, Robson PJ, eds. The medicinal uses of cannabis and cannabinoids. Londýn: Pharmaceutical Press 2004. 71-79, 13-129, 141-197.
    2. Russo EB. History of cannabis and its preparations in Sage, Science and Sobriquet. Chem Biodiv 2007; 4(8): 1614-1648. Go to original source... Go to PubMed...
    3. Flores-Sanchez IJ, Verpoorte R. Secondary metabolism in Cannabis. Phytochem Rev 2008; 7: 615-639. Go to original source...
    4. www.cannabisoffice.nl/eng/index.html; Specification Bedrocan, Bedrobinol and Bediol. Information for physicians and pharmacists (3. 3. 2009).
    5. European Pharmacopoeia 6th Edition, 2008 (6.2); http://www.edqm.eu/site/Online_Publications-581.html (15. 10. 2008).
    6. Kolektiv autorů. Český lékopis 2005. Praha: Grada 2005.
    7. http://www.hc-sc.gc.ca/dhp-mps/marihuana/index-eng.php (3. 3. 2009).
    8. http://www.gwpharm.com (3. 3. 2009); obrázek Sativex: http://marijuanamouthspray.com.
    9. http://www.prairieplant.com/medicinal-marijuana.htm (3. 3. 2009).
    10. http://www.medicalmarijuana.org (3. 3. 2009).
    11. Benyamina A, Lecacheux M, Blecha L, et al. Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Rev Neurother 2008; 8(3): 479-491. Go to original source... Go to PubMed...
    12. Budney AJ, Roffman R, Stephens RS, et al. Marijuana dependence and its treatment. Addict Sci Clin Pract 2007; (4)1: 4-16. Go to original source... Go to PubMed...
    13. Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 2009; 56: 235-243. Go to original source... Go to PubMed...
    14. Mennes CE, Abdallah AB, Cottler EB. The reliability of self-reported cannabis abuse, dependence and withdrawal symptoms: Multiside study of differences between general population and treatment groups. Addict Behav 2009; 34: 223-226. Go to original source... Go to PubMed...
    15. Di Forty M, Morrison PD, Butt A, et al. Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? Curr Opin Psychiatry 2007; 20: 228-234. Go to original source... Go to PubMed...
    16. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodiv 2007; 4(8): 1744-1769. Go to original source... Go to PubMed...
    17. Richer I, Bergeron J. Driving under the influence of cannabis: Links with dangerous driving, psychological predictors, and accident involvement. Accid Anal Prevent 2009; doi: 10.1016/j. aap. 2008. 12. 004. Go to original source... Go to PubMed...
    18. ElSohly MA, Slade D. Chemical constituents of marihuana: The complex mixture of natural cannabinoids. Life Sci 2005; 78: 539-548. Go to original source... Go to PubMed...
    19. Botta B, Gacs-Baitz E, Vinciguerra V, et al. Three isoflavanones with cannabinoid-like moieties from Desmodium canum. Phytochemistry 2003; 64: 599-602. Go to original source... Go to PubMed...
    20. Toyota M, Kinugawa T, Asakawa Y. Bibenzyl cannabinoid and bibenzyl derivative from the liverworth Radula parrottetii. Phytochemistry 1994; 37(3): 859-862. Go to original source...
    21. Bisogno T. Endogenous cannabinoids: Structure and metabolism. J Neuroendocrinol 2008; Suppl 1/20: 1-9. Go to original source... Go to PubMed...
    22. Bisogno T, Di Marzo V. Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacol Res 2007; 56: 428-442. Go to original source... Go to PubMed...
    23. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as en emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462. Go to original source... Go to PubMed...
    24. Partwee RG. The diverse CB1 and CB2 receptor pharmacology of the three plant cannabinoids. Br J Pharmacol 2008; 153: 199-215. Go to original source... Go to PubMed...
    25. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006; 105: 1-25. Go to original source... Go to PubMed...
    26. Klein TW, Newton CT. Therapeutic potential of cannabnoid-based drugs. In: Surin MR, Smolkin YS eds. Immune madiated disseases. New York: Springer 2007; 601, 395-413. Go to original source...
    27. Micromedex(R) Healthcare Series. Thomson Micromedex. http://www.thomsonhc.com (20. 5. 2008).
    28. http://www.cesamet.net; full prescribing information (3. 3. 2009).
    29. http://www.solvaypharmaceuticals-us.com/products/marinolproductinformation/0,,12413-2-0,00.htm (3. 3. 2009).
    30. Bellocchio L, Vicennati V, Cervin C, et al. The endocannabnoid system in the regulation of cardiometabolic risk factor. Am J Cardiol 2007; 100: 7P-17P. Go to original source... Go to PubMed...
    31. Mitchel PB, Morris MJ. Depression and anxiety with rimonabant. Lancet 2007; 370: 1671-1672. Go to original source... Go to PubMed...
    32. Wang J, Ueda N. Role of the endocannabinoid system in metabolic control. Curr Opin Nephrol Hypertens 2008; 17: 1-10. Go to original source... Go to PubMed...
    33. http://www.sukl.cz/pozastaveni-registrace-acomplia (3. 3. 2009).
    34. Centonze D, Finazzi-Agró A, Bernardi G, et al. The endocannabinoid system in targeting inflammatori neurodegenerative diseases. Trends Pharmacol Sci 2007; 28(4): 180-187. Go to original source... Go to PubMed...
    35. Flygare J, Sander B. The endocannabinoid system in cancer - Potential therapeutic target? Seminars in cancer biology 2008; doi. 10.1016/j.semcancer. 2007. 12. 008. Go to original source... Go to PubMed...
    36. Lienau FS, Fülgraf H, Moser A, et al. Why do cannabnoids not show consistent effects as analgetic drugs in multiple sclerosis? Eur J Neurol 2007; 14: 1162-1169. Go to original source... Go to PubMed...
    37. Micale V, Mazzola C, Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol Res 2007; 56: 382-392. Go to original source... Go to PubMed...
    38. Nurmiko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuroathic pain characterised by allodinia: A randomised, double-blind, placebo-controlled clinical trial. Pain 2007; 133: 210-220. Go to original source... Go to PubMed...
    39. http://www.storz-bickel.com/vaporizer/volcano-vaporization-system.html (3. 3. 2009).
    40. Seamon JM, Fass JA, Maniscalco-Feichti M, et al. Medical marijuana and the developing role of the pharmacist. Am J Health-Syst Pharm 2007; 64: 1037-1044. Go to original source... Go to PubMed...
    41. Comelli F, Giagnoni E, Bettoni I, et al. Antihyperalgesic effects of a Cannabis sativa exract in a rat model of neuropathic pain: Mechanisms involved. Phytother Res 2008; 22: 1017-1024. Go to original source... Go to PubMed...
    42. Radwan MM, ElSohly MA, Slade D, et al. Non-cannabinoid constituents from a high potency Cannabis sativa variety. Phytochemistry, 2008; doi: 10.1016/j.phytochem. 2008. 07. 010. Go to original source...
    43. Jang J, Na M, Thuong PT, et al. Prenylated flavonoids with PTP1B inhibitory activity from the root bark of Erithryna mildbraedii. Chem Pharm Bul 2008; 56(1): 85-88. Go to original source... Go to PubMed...
    44. Kovács A, Forgo P, Zupkó I, et al. Phenanthrenes and dihydrophenanthrene from Tamus communis and their cytotoxic activity. Phytochemistry 2007; 68: 687-691. Go to original source... Go to PubMed...
    45. Lee KY, Sung SH, Kim YC. Neuroprotective bibenzyl glycosides of Stemona tuberosa roots. J Nat Prod 2006; 69: 679-681. Go to original source... Go to PubMed...
    46. Lin L, Yang X, Tang C, et al. Antibacterial stilbenoids from the roots of Stemona tuberosa. Phytochemistry 2008; 69: 457-463. Go to original source... Go to PubMed...
    47. Gersch J, Leonti M, Raduner S, et al. Beta-caryophyllene is a dietary cannabinoid. PNAS 2008; 105(26): 9099-9104. Go to original source... Go to PubMed...
    48. Ma CY, Liu WK, Che CT. Lignanamides and nonalkaloid components of Hyoscyamus niger seeds. J Nat Prod 2002; 65: 206-209. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.